Patient care could be affected by pathologist overestimation of malignant cells
, which could generate a false-negative test result for a mutation.
Two cases were suspicious for malignant cells
. (Table 4) Sixteen (17.20%) cases showed definite cytological evidence of malignancy 13 being female and 3 were males.
The malignant cells
were negative for markers of B-cell differentiation (CD20 and CD79a) and T-cell differentiation (CD3 and CD45RO), and expressed markers associated with immature myeloid cells (CD34, CD43, myeloperoxidase, and lysozyme).
* A novel treatment for prostate cancer uses heat from implanted magnetic rods to destroy malignant cells
. Doctors at the University of Iowa explain that a low magnetic field, not commonly found in everyday life, is used to activate the cobalt and palladium rods.
23 August 2011 - US-based healthcare provider Mayo Clinic reported yesterday that it obtained investigational new drug approval from the US Food and Drug Administration (FDA) for two new cancer vaccines that mobilise the body's defense mechanisms to destroy malignant cells
In several kinds of cancer, malignant cells
display an excess of a specific type of surface receptor, which when stimulated causes unchecked growth of such cells (SN: 9/11/04, p.
(8) The reasons for these higher risks are not clear, but two causes have been postulated: (1) immune dysregulation, which alters the immune system's ability to identify and destroy malignant cells
, and (2) repeated or chronic antigen stimulation, which may lead to abnormal immune system activation.
Decitabine's unique mechanism of action - inhibition of DNA hypermethylation - specifically targets the series of events that lead to the formation of malignant cells
. Silencing suppressor genes via hypermethylation is an early key event in the development of cancer.
The nanoparticles are coated in a sugar-like substance to attract even the most remote malignant cells
Immunoperoxidase stains performed on the paraffin-embedded tissue block showed intense staining of the large malignant cells
by CD20 (membrane), CD10 (membrane), and Bcl-2 (cytoplasmic).
(Tustin, CA) has patented a method for measuring the effectiveness of therapy intended to kill malignant cells
in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells
in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component.
"An early signal, in the form of compression, appears to get these malignant cells
back on the right track," he stated.